

S 2665

A bill to require guidance on how the Food and Drug Administration will consider claims of opioid sparing and on the conditions under which the Food and Drug Administration will consider misuse and abuse of drugs in making certain determinations of safety.

Congress: 115 (2017–2019, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Apr 12, 2018

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Apr 12, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/senate-bill/2665>

Sponsor

Name: Sen. Young, Todd [R-IN]

Party: Republican • **State:** IN • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Donnelly, Joe [D-IN]	D · IN		Apr 12, 2018

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Apr 12, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 S 2680	Related bill	May 7, 2018: Placed on Senate Legislative Calendar under General Orders. Calendar No. 398.

Summary (as of Apr 12, 2018)

This bill requires the Food and Drug Administration (FDA) to develop guidance regarding how it will assess evidence to support claims of opioid sparing (i.e., the use of drugs that reduce pain while also allowing reduced use or avoidance of oral opioids) for non-opioid or other non-addictive medical products intended to treat pain.

The FDA must also develop guidance regarding how it will consider the misuse and abuse of drugs in making certain determinations of safety.

Actions Timeline

- **Apr 12, 2018:** Introduced in Senate
- **Apr 12, 2018:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.